Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A (US)
Hemophilia A is a monogenic X-linked recessive bleeding disorder caused by the deficiency of clotting factor VIII. Prophylaxis, the typical care for hemophilia A patients, is especially preferred for patients with severe cases because it aims to reduce bleeding episodes and long-term joint complications. Hemlibra and factor VIII replacements are the standard of care for the management of inhibitor-naive patients, while therapies like Altuviiio and Hympavzi are important treatment alternatives that offer more-convenient dosing options. Roctavian, once considered a transformative therapy, faces adoption challenges due to variable long-term efficacy data affecting reimbursement and market access. Understanding the multifaceted decision points that hematologists encounter when treating inhibitor-naive hemophilia A patients is crucial for developers entering this market. This report provides a comprehensive analysis of the hemophilia A prophylaxis treatment landscape, with emphasis on inhibitor-naive patients.
QUESTIONS ANSWERED
- Which product attributes do U.S. hematologists perceive as most important for treatment of their hemophilia A patients?
- How do factors such as mode of drug administration, drug delivery, and formulary access influence choice of therapy?
- What patient shares do the FVIII replacement therapies garner among inhibitor-naive hemophilia A patients by severity? Which therapies are most preferred among the FVIII replacements?
- What will be the impact of novel agents such as Altuviiio and Hympavzi for the inhibitor-naive hemophilia A market? What will drive use of such therapies, and what will be their source of business?
- What are the recent and anticipated changes in hemophilia A treatment practices?
CONTENT HIGHLIGHTS
Geographies: United States.
Primary research: Survey of 100 hematologists.
Key drugs covered: Hemlibra, Altuviiio, Hympavzi, (SHL and EHL) recombinant factor VIII replacement therapies, Roctavian.
PRODUCT DESCRIPTION
Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:
- Understand the treatment landscape for a disease and how physicians make prescribing decisions.
- Evaluate the drivers and obstacles that influence treatment selection.
- Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
